ClinicalTrials.gg
CompletedNCT01807650BSG-12Updated Jul 19, 2018Results posted

Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)

A Phase 3 interventional study of Oleogel-S10, non-adhesive wound dressing and Non-adhesive wound dressing only in Wounds, sponsored by Birken AG. Completed at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-19.

Sponsored by Birken AG (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this phase III clinical trial was to show safety and efficacy of Oleogel-S10 in accelerating the wound healing of Split-Thickness Skin Graft (STSG) donor sites.

Read the detailed description

Oleogel-S10 has shown efficacy and was well tolerated in previous clinical trials in participants with skin lesions. Especially the results in a previous study with STSG donor sites suggested that Oleogel-S10 should be efficacious and safe in the treatment of superficial wounds.

The present phase III clinical trial in STSG donor sites was initiated to demonstrate wound healing progress, i.e., the time to healing and the grade of epithelialization of the wound.

In this study, STSG donor sites were separated into 2 wound halves. Randomly assigned, 1 wound half was treated with Oleogel-S10 and non-adhesive wound dressing, the other wound half with non-adhesive wound dressing only (standard of care).

Wound healing progress was documented by photos which were assessed by expert reviewers blinded to the treatment of the wound halves.

02

Conditions studied

  • Wounds

Browse trials for

Keywords

  • Split-Thickness Skin Graft (STSG) donor site
  • Split-thickness skin graft
  • STSG
  • Wound healing
  • Skin grafting
  • Superficial wound
  • Partial-thickness wound
  • Time to wound closure
03

In context

Wounds and Injuries

2,218 studies on the registry are indexed under Wounds and Injuries; 440 are open to participants now.

This study's enrollment of 112 is above the median of 70 across 1,423 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Birken AG is the lead sponsor of 6 studies on the registry; none are open to participants now.

First submitted before Birken AG became part of Chiesi Farmaceutici S.p.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants at least 18 years old who have provided written
  • Presenting a split-thickness skin graft donor site wound with a minimum size of 15 cm2 and with a minimum width of 3 cm.
  • Participant was able to understand the Informed Consent Form (ICF) provided and was prepared to comply with all study requirements, including the following: Visiting the trial site for wound dressing change and photo documentation every third or fourth day until both wound halves were closed (but no longer than 28 days after surgery).
  • Willing to perform all necessary wound dressing changes at the trial site. Also the participant needed to agree to return to site for 3 and 12 months follow-up visits.
  • Women of who were in the period between menarche and menopause needed to apply a highly effective method of (failure rate less than 1% per year when used consistently and correctly (e.g., implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices [IUDs], sexual abstinence, or a vasectomized partner). Birth control method needed to have been applied for at least 1 monthly cycle prior to first administration of study drug, be maintained during the study treatment phase and continued for at least 30 days after the last administration of study drug. Sexually active, non-vasectomized men needed to use a barrier method (condoms) during the treatment phase of this clinical trial.

Exclusion criteria

Exclusion Criteria:

  • Diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety or efficacy.
  • A skin disorder that was chronic or currently active and which the Investigator considered would adversely affect the healing of the acute wounds or involved the areas to be examined in this trial.
  • A history of to any of the drugs, surgical dressings or to be used in this trial.
  • Known multiple allergic disorders.
  • Taking, or have taken, any drugs within 3 months prior to the screening visit.
  • Pregnant or breast feeding women were not allowed to participate in the study.
  • Inappropriate to participate in the study, for any reason, in the opinion of the investigator.
  • Mental incapacity or language barriers precluding adequate understanding the ICF or co-operation or willingness to follow study procedures.
  • Previous participation in this study.
  • Employee at the investigational site, relative or spouse of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Oleogel-S10, non-adhesive wound dressing

    A split-thickness skin graft (STSG) donor site wound \>15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.

    Drug: Oleogel-S10, non-adhesive wound dressing

  • Other
    Non-adhesive wound dressing only

    A STSG donor site wound \>15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days.

    Device: Non-adhesive wound dressing only

Interventions

  • 1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28

    Also known as: Episalvan®

  • DeviceNon-adhesive wound dressing only

    Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28

    Also known as: Mepilex®

06

What researchers measure

Primary outcomes

  1. Intra-individual Difference in Time to Wound Closure

    Intra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing only. Independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound half that were taken before start of treatment, during wound dressing changes and at the end of treatment. Difference in time to wound closure was calculated for every individual participant as \[time taken for wound half treated with Oleogel-S10 to close\] - \[time taken for wound half treated with non-adhesive wound dressing to close\], i.e., results below 0 indicate earlier wound closure of Oleogel-S10 treatment. The overall mean difference in time to wound closure was calculated based on all mean differences in time to wound closure of individual participants. Hence, primary outcome data derived from mean difference in time to wound closure by participant.

    Time frame: 2 to 4 weeks

Secondary outcomes

  1. Time From Surgery Until Wound Closure is Achieved

    Time from surgery until wound closure is achieved, separately for wound halves treated with Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only. While outcome measure 1 (intra-individual difference in time to wound closure) was calculated based on mean intra-individual difference in time to wound closure in 110 participants with missing values replaced by a value of 0, for outcome measure 2 missing values were not replaced. For 2 of the 110 wounds data were missing, thus the reported values are calculated from 108 STSG donor site wound halves by intervention (Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only).

    Time frame: 2 to 4 weeks

  2. Percentage of Participants With Earlier Healing

    Percentage of participants with earlier healing of wound area treated with Oleogel-S10 and non-adhesive wound dressing compared to non-adhesive wound dressing only

    Time frame: 2 to 4 weeks

  3. Percentage of Participants With Wound Closure at Different Time Points

    For separate time points (Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28), the frequencies of wound areas which have reached wound closure were calculated.

    Time frame: 2 to 4 weeks

  4. Percentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator

    A study team member assessed the progress of wound healing by treatment regimen and noted the degree of epithelialization (expressed in percent of the original wound size) at wound dressing changes on Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28.

    Time frame: 2 to 4 weeks

  5. Likert Scale Rating of Efficacy

    Participants and investigators were asked to grade the efficacy of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only on a 5-point Likert scale (treatment with Oleogel-S10 is much more effective, treatment with Oleogel-S10 is more effective, both treatments have the same efficacy, non-adhesive wound dressing only is more effective, non-adhesive wound dressing only is much more effective).

    Time frame: 2 to 4 weeks

  6. Cosmetic Outcome at 3 and 12 Months After Surgery, Respectively

    Blinded photographic evaluation which wound half resembles more closely the surrounding skin with regard to texture, redness, growth of hair, and pigmentation.

    Time frame: 3 months and 12 months

  7. Likert Scale Rating of Tolerability

    Participants and investigators were asked to evaluate the tolerability of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only (standard of care) on a 5-point Likert scale (treatment with Oleogel-S10 is much better tolerated, treatment with Oleogel-S10 is better tolerated, both treatments are equally well tolerated, non-adhesive wound dressing only is better tolerated, non-adhesive wound dressing only is much better tolerated).

    Time frame: 2 to 4 weeks

  8. Pharmacokinetic (PK) Data (Number of Plasma Samples With Measurable Betulin Concentration)

    Systemic presence/concentration of betulin in blood plasma samples. Plasma samples were collected in weekly intervals and at the end of treatment (when wound closure was achieved or at Day 28). Samples were analysed in a central laboratory with a validated LC-MS/MS method with a lower limit of quantification (LLOQ) of 1 ng/mL.

    Time frame: up to 4 weeks

  9. Pharmacokinetic (PK) Data (Plasma Betulin Concentration)

    Systemic presence/concentration of betulin in blood plasma samples - values for the number of samples with measurable values in samples above the lower limit of quantification (LLOQ) of 1 ng/mL

    Time frame: up to 4 weeks

  10. Frequency of Adverse Events

    Time frame: Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).

  11. Severity of Adverse Events

    Adverse Events were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) as being mild (NCI CTCAE Grade 1), moderate (NCI CTCAE Grade 2), severe (NCI CTCAE Grade 3), life-threatening (NCI CTCAE Grade 4) or death (NCI CTCAE Grade 5).

    Time frame: Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).

  12. Adverse Events by Relationship to Study Medication

    Adverse events were assessed as being 'unlikely', 'possibly' or 'probably' related to study medication, 'not related' to study medication or the relationship to study medication was rated as 'unknown'.

    Time frame: Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).

07

Results

Posted Jul 19, 2018

Participant flow

Participants were enrolled from 04 Apr 2013 to 04 Sep 2013 in 14 clinical centers in 4 countries: Spain (6 centers), Greece (3 centers), Latvia (2 centers), and France (3 centers).

Participant flow — Overall Study
MilestoneEntire Study Population
Started112
Completed92
Not completed20
Withdrew: Lack of full wound closure at day 2813
Withdrew: Adverse event5
Withdrew: Other2

Outcome measures

PrimaryIntra-individual Difference in Time to Wound Closure

Intra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing only. Independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound half that were taken before start of treatment, during wound dressing changes and at the end of treatment. Difference in time to wound closure was calculated for every individual participant as \[time taken for wound half treated with Oleogel-S10 to close\] - \[time taken for wound half treated with non-adhesive wound dressing to close\], i.e., results below 0 indicate earlier wound closure of Oleogel-S10 treatment. The overall mean difference in time to wound closure was calculated based on all mean differences in time to wound closure of individual participants. Hence, primary outcome data derived from mean difference in time to wound closure by participant.

Time frame:
2 to 4 weeks
Reported as:
Mean · days
Intra-individual Difference in Time to Wound Closure
daysEntire Study Population
Intra-individual Difference in Time to Wound Closure-0.8 (-1.5 to -0.1)
Statistical analysis
  • Entire Study Population · t-test, 2 sided · p = =0.0232 (2-sided, significance level = 0.05)
SecondaryTime From Surgery Until Wound Closure is Achieved

Time from surgery until wound closure is achieved, separately for wound halves treated with Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only. While outcome measure 1 (intra-individual difference in time to wound closure) was calculated based on mean intra-individual difference in time to wound closure in 110 participants with missing values replaced by a value of 0, for outcome measure 2 missing values were not replaced. For 2 of the 110 wounds data were missing, thus the reported values are calculated from 108 STSG donor site wound halves by intervention (Oleogel-S10 and non-adhesive wound dressing vs. non-adhesive wound dressing only).

Time frame:
2 to 4 weeks
Reported as:
Mean · Days from surgery until wound closure
Time From Surgery Until Wound Closure is Achieved
Days from surgery until wound closureOleogel-S10 and Non-adhesive Wound DressingNon-adhesive Wound Dressing Only
Time From Surgery Until Wound Closure is Achieved15.1 (14.1 to 16.1)16.0 (14.8 to 17.1)
SecondaryPercentage of Participants With Earlier Healing

Percentage of participants with earlier healing of wound area treated with Oleogel-S10 and non-adhesive wound dressing compared to non-adhesive wound dressing only

Time frame:
2 to 4 weeks
Reported as:
Number · Percentage with earlier healing
Percentage of Participants With Earlier Healing
Percentage with earlier healingOleogel-S10 and Non-adhesive Wound DressingNon-adhesive Wound Dressing Only
Percentage of Participants With Earlier Healing45.5 (35.9 to 55.2)30.0 (21.6 to 39.5)
SecondaryPercentage of Participants With Wound Closure at Different Time Points

For separate time points (Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28), the frequencies of wound areas which have reached wound closure were calculated.

Time frame:
2 to 4 weeks
Reported as:
Number · Percentage with wound closure
Percentage of Participants With Wound Closure at Different Time Points
Percentage with wound closureOleogel-S10 and Non-adhesive Wound DressingNon-adhesive Wound Dressing Only
Day 72.8 (0.6 to 7.9)3.7 (1.0 to 9.2)
Day 1014.8 (8.7 to 22.9)8.3 (3.9 to 15.2)
Day 1448.1 (38.4 to 58.0)48.1 (38.4 to 58.0)
Day 1879.6 (70.8 to 86.8)71.3 (61.8 to 79.6)
Day 2186.1 (78.1 to 92.0)80.6 (71.8 to 87.5)
Day 2896.3 (90.8 to 99.0)91.7 (84.8 to 96.1)
SecondaryPercentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator

A study team member assessed the progress of wound healing by treatment regimen and noted the degree of epithelialization (expressed in percent of the original wound size) at wound dressing changes on Day 7, Day 10, Day 14, Day 18, Day 21, and Day 28.

Time frame:
2 to 4 weeks
Reported as:
Mean · Area Percent of initial wound size
Percentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator
Area Percent of initial wound sizeOleogel-S10 and Non-adhesive Wound DressingNon-adhesive Wound Dressing Only
Day 727.4 (21.5 to 33.3)21.3 (16.4 to 26.3)
Day 1048.6 (41.6 to 55.6)42.5 (36.1 to 48.8)
Day 1480.6 (75.2 to 86.0)74.9 (68.9 to 81.0)
Day 1890.9 (87.2 to 94.6)85.0 (80.3 to 89.9)
Day 2194.0 (91.0 to 97.1)88.5 (84.2 to 92.8)
Day 2896.4 (94.0 to 98.7)92.8 (89.3 to 96.3)
Statistical analysis
  • Oleogel-S10 and Non-adhesive Wound Dressing vs Non-adhesive Wound Dressing Only · t-test, 2 sided · p = =0.0005 (Day 7) · Mean difference (final values): 6.1 · 95% CI 2.7 to 9.4Mean difference in degree of epithelialization \[%\] (Oleogel-S10 and non-adhesive wound dressing minus non-adhesive wound dressing only)
  • Oleogel-S10 and Non-adhesive Wound Dressing vs Non-adhesive Wound Dressing Only · t-test, 2 sided · p = =0.0002 (Day 10) · Mean difference (final values): 6.2 · 95% CI 3.0 to 9.4Mean difference in degree of epithelialization \[%\] (Oleogel-S10 and non-adhesive wound dressing minus non-adhesive wound dressing only)
  • Oleogel-S10 and Non-adhesive Wound Dressing vs Non-adhesive Wound Dressing Only · t-test, 2 sided · p = =0.0028 (Day 14) · Mean difference (final values): 5.6 · 95% CI 2.0 to 9.3Mean difference in degree of epithelialization \[%\] (Oleogel-S10 and non-adhesive wound dressing minus non-adhesive wound dressing only)
  • Oleogel-S10 and Non-adhesive Wound Dressing vs Non-adhesive Wound Dressing Only · t-test, 2 sided · p = =0.0009 (Day 18) · Mean difference (final values): 5.9 · 95% CI 2.5 to 9.3Mean difference in degree of epithelialization \[%\] (Oleogel-S10 and non-adhesive wound dressing minus non-adhesive wound dressing only)
  • Oleogel-S10 and Non-adhesive Wound Dressing vs Non-adhesive Wound Dressing Only · t-test, 2 sided · p = =0.0003 (Day 21) · Mean difference (final values): 5.6 · 95% CI 2.6 to 8.6Mean difference in degree of epithelialization \[%\] (Oleogel-S10 and non-adhesive wound dressing minus non-adhesive wound dressing only)
  • Oleogel-S10 and Non-adhesive Wound Dressing vs Non-adhesive Wound Dressing Only · t-test, 2 sided · p = =0.0145 (Day 28) · Mean difference (final values): 3.6 · 95% CI 0.7 to 6.4Mean difference in degree of epithelialization \[%\] (Oleogel-S10 and non-adhesive wound dressing minus non-adhesive wound dressing only)
SecondaryLikert Scale Rating of Efficacy

Participants and investigators were asked to grade the efficacy of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only on a 5-point Likert scale (treatment with Oleogel-S10 is much more effective, treatment with Oleogel-S10 is more effective, both treatments have the same efficacy, non-adhesive wound dressing only is more effective, non-adhesive wound dressing only is much more effective).

Time frame:
2 to 4 weeks
Reported as:
Number · Percentage of efficacy assessments
Likert Scale Rating of Efficacy
Percentage of efficacy assessmentsInvestigator Asssessment Day 7Investigator Assessment Day 14Investigator Assessment Day 21Investigator Assessment Day 28Investigator Assessment End of TreatmentParticipant Assessment Day 7Participant Assessment Day 14Participant Assessment Day 21Participant Assessment Day 28Participant Assessment EoT
Oleogel-S10 much more effective4.7 (1.5 to 10.6)13.6 (7.6 to 21.8)16.8 (10.1 to 25.6)17.8 (10.9 to 26.7)17.1 (10.5 to 25.7)7.7 (3.4 to 14.6)15.0 (8.6 to 23.5)16.2 (9.5 to 24.9)15.3 (8.8 to 24.0)14.7 (8.5 to 23.1)
Oleogel-S10 more effective44.9 (35.2 to 54.8)35.0 (25.8 to 45.0)36.6 (27.3 to 46.8)33.7 (24.6 to 43.8)35.2 (26.2 to 45.2)31.7 (22.9 to 41.6)36.0 (26.6 to 46.2)35.4 (26.0 to 45.6)35.7 (26.3 to 46.0)36.3 (27.0 to 46.4)
Both treatments same efficacy40.2 (30.8 to 50.1)40.8 (31.2 to 50.9)36.6 (27.3 to 46.8)37.6 (28.2 to 47.8)37.1 (27.9 to 47.1)53.8 (43.8 to 63.7)38.0 (28.5 to 48.3)39.4 (29.7 to 49.7)38.8 (29.1 to 49.2)39.2 (29.7 to 49.4)
Standard of care (SOC) more effective9.3 (4.6 to 16.5)10.7 (5.5 to 18.3)9.9 (4.9 to 17.5)9.9 (4.9 to 17.5)9.5 (4.7 to 16.8)6.7 (2.7 to 13.4)11.0 (5.6 to 18.8)8.1 (3.6 to 15.3)8.2 (3.6 to 15.5)7.8 (3.4 to 14.9)
SOC much more effective0.9 (0.0 to 5.1)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)1.0 (0.0 to 5.4)1.0 (0.0 to 5.2)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)1.0 (0.0 to 5.5)2.0 (0.2 to 7.2)2.0 (0.2 to 6.9)
SecondaryCosmetic Outcome at 3 and 12 Months After Surgery, Respectively

Blinded photographic evaluation which wound half resembles more closely the surrounding skin with regard to texture, redness, growth of hair, and pigmentation.

Time frame:
3 months and 12 months
Reported as:
Number · Percentage of wounds
Cosmetic Outcome at 3 and 12 Months After Surgery, Respectively
Percentage of woundsTexture at 3 Months Follow-upHair Growth at 3 Months Follow-upPigmentation at 3 Months Follow-upRedness at 3 Months Follow-upTexture at 12 Months Follow-upHair Growth at 12 Months Follow-upPigmentation at 12 Months Follow-upRedness at 12 Months Follow-up
Wound half treated with Oleogel-S1018.9 (11.6 to 28.3)1.1 (0.0 to 5.7)32.6 (23.4 to 43.0)25.3 (16.9 to 35.2)13.8 (6.5 to 24.7)0.0 (0.0 to 0.0)27.7 (17.3 to 40.2)15.4 (7.6 to 26.5)
Wound half treated with wound dressing only8.4 (3.7 to 15.9)0.0 (0.0 to 0.0)13.7 (7.5 to 22.3)14.7 (8.3 to 23.5)3.1 (0.4 to 10.7)0.0 (0.0 to 0.0)9.2 (3.5 to 19.0)4.6 (1.0 to 12.9)
Both equal71.6 (61.4 to 80.4)98.9 (94.3 to 100.0)50.5 (40.1 to 60.9)56.8 (46.3 to 67.0)83.1 (71.7 to 91.2)100.0 (94.5 to 100.0)60.0 (47.1 to 72.0)80.0 (68.2 to 88.9)
SecondaryLikert Scale Rating of Tolerability

Participants and investigators were asked to evaluate the tolerability of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only (standard of care) on a 5-point Likert scale (treatment with Oleogel-S10 is much better tolerated, treatment with Oleogel-S10 is better tolerated, both treatments are equally well tolerated, non-adhesive wound dressing only is better tolerated, non-adhesive wound dressing only is much better tolerated).

Time frame:
2 to 4 weeks
Reported as:
Number · Percentage of participants
Likert Scale Rating of Tolerability
Percentage of participantsInvestigator Asssessment Day 7Investigator Assessment Day 14Investigator Assessment Day 21Investigator Assessment Day 28Investigator Assessment End of TreatmentParticipant Assessment Day 7Participant Assessment Day 14Participant Assessment Day 21Participant Assessment Day 28Participant Assessment EoT
Oleogeogel-S10 much better tolerated5.48.911.612.513.48.013.416.115.216.1
Oleogel-S10 better tolerated30.433.928.626.828.923.229.526.825.927.7
Both treatments equally well tolerated58.944.646.448.249.158.037.537.540.241.1
SOC better tolerated2.75.43.63.63.63.68.97.15.45.4
SOC much better tolerated0.00.00.90.00.00.00.00.90.90.9
SecondaryPharmacokinetic (PK) Data (Number of Plasma Samples With Measurable Betulin Concentration)

Systemic presence/concentration of betulin in blood plasma samples. Plasma samples were collected in weekly intervals and at the end of treatment (when wound closure was achieved or at Day 28). Samples were analysed in a central laboratory with a validated LC-MS/MS method with a lower limit of quantification (LLOQ) of 1 ng/mL.

Time frame:
up to 4 weeks
Reported as:
Number · Plasma Samples
Pharmacokinetic (PK) Data (Number of Plasma Samples With Measurable Betulin Concentration)
Plasma SamplesDay 0 (Pre-dose)Treatment Period
Samples below LLOQ (<1 ng/mL)110271
Samples above LLOQ213
Samples without valid result06
SecondaryPharmacokinetic (PK) Data (Plasma Betulin Concentration)

Systemic presence/concentration of betulin in blood plasma samples - values for the number of samples with measurable values in samples above the lower limit of quantification (LLOQ) of 1 ng/mL

Time frame:
up to 4 weeks
Reported as:
Mean · Betulin (ng/mL)
Pharmacokinetic (PK) Data (Plasma Betulin Concentration)
Betulin (ng/mL)Day 0 (Pre-dose)Treatment Period
Pharmacokinetic (PK) Data (Plasma Betulin Concentration)24.0 (4.1 to 43.9)10.4 (1.1 to 68.6)
SecondaryFrequency of Adverse Events
Time frame:
Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).
Reported as:
Number · Participants with adverse events (%)
Frequency of Adverse Events
Participants with adverse events (%)Entire Study Population
Adverse events (AEs)53.6
Serious adverse events4.5
AEs leading to discontinuation3.6
Related AEs14.3
Application site reactions24.1
Non treatment-emergent AEs7.1
SecondarySeverity of Adverse Events

Adverse Events were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) as being mild (NCI CTCAE Grade 1), moderate (NCI CTCAE Grade 2), severe (NCI CTCAE Grade 3), life-threatening (NCI CTCAE Grade 4) or death (NCI CTCAE Grade 5).

Time frame:
Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).
Reported as:
Number · Participants with adverse events (%)
Severity of Adverse Events
Participants with adverse events (%)Entire Study Population
Mild (CTCAE Grade 1)40.2
Moderate (CTCAE Grade 2)27.7
Severe (CTCAE Grade 3)7.1
Life-Threatening (CTCAE Grade 4)2.7
Death (CTCAE Grade 5)0.0
SecondaryAdverse Events by Relationship to Study Medication

Adverse events were assessed as being 'unlikely', 'possibly' or 'probably' related to study medication, 'not related' to study medication or the relationship to study medication was rated as 'unknown'.

Time frame:
Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).
Reported as:
Number · Participants with adverse events (%)
Adverse Events by Relationship to Study Medication
Participants with adverse events (%)Entire Study Population
'Unlikely' related2.7
'Possibly' related5.4
'Probably' related8.0
Unknown relationship1.8
No relationship47.3

Adverse events

Collected over Day 0 (start of treatment) until end of treatment (Day 28 or earlier if full wound closure was achieved earlier).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entire Study Population - Systemic Adverse Events (AE)—4/112 (3.6%)30/112 (26.8%)
Oleogel-S10 Localized Adverse Event (AE)—0/112 (0%)2/112 (1.8%)
Non-adhesive Wound Dressing Localized AE—0/112 (0%)4/112 (3.6%)
Localized AE Both Wound Halves—1/112 (0.9%)9/112 (8%)
Entire Study Population -Systemic and Localized AEs—5/112 (4.5%)40/112 (35.7%)
Most frequent serious events
Most frequent serious events
EventEntire Study Population - Systemic Adverse Events (AE)Oleogel-S10 Localized Adverse Event (AE)Non-adhesive Wound Dressing Localized AELocalized AE Both Wound HalvesEntire Study Population -Systemic and Localized AEs
Wound infectionInfections and infestations0/1120/1120/1121/1121/112
SepsisInfections and infestations1/1120/1120/1120/1121/112
Postoperative wound complicationInjury, poisoning and procedural complications1/1120/1120/1120/1121/112
ManiaPsychiatric disorders1/1120/1120/1120/1121/112
BacteremiaInfections and infestations1/1120/1120/1120/1121/112
BronchospasmRespiratory, thoracic and mediastinal disorders1/1120/1120/1120/1121/112
Most frequent other events
Most frequent other events
EventEntire Study Population - Systemic Adverse Events (AE)Oleogel-S10 Localized Adverse Event (AE)Non-adhesive Wound Dressing Localized AELocalized AE Both Wound HalvesEntire Study Population -Systemic and Localized AEs
PyrexiaGeneral disorders12/1120/1120/1120/11212/112
Pain of skinSkin and subcutaneous tissue disorders4/1120/1122/1124/11210/112
Skin infectionInfections and infestations2/1121/1122/1124/1129/112
PruritusSkin and subcutaneous tissue disorders5/1121/1120/1123/1129/112
ConstipationGastrointestinal disorders8/1120/1120/1120/1128/112
AnemiaBlood and lymphatic system disorders6/1120/1120/1120/1126/112
PainGeneral disorders6/1120/1120/1120/1126/112

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years0
Between 18 and 65 years89
>=65 years23
Age, Continuous
Age, Continuous(years)Entire Study Population
Median49 (19 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female39
Male73
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
Greece14
Latvia31
France11
Spain56
08

Study locations

14 sites
  • CHU de Bordeaux
    Bordeaux, France
  • Hôpital de la Conception
    Marseille, France
  • CHU de Nantes
    Nantes, France
  • KAT General Hospital of Attica
    Athens, Greece
  • National University, "Andreas Syggros" Skin & Venereal Diseases Hospital
    Athens, Greece
  • Aristotle University General Hospital
    Thessaloniki, Greece
  • Riga East University Hospital, Microsurgery Center
    Riga, Latvia
  • Riga East University Hospital, State Burn Center
    Riga, Latvia
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario de Getafe
    Madrid, Spain
  • Hopital Universitari i Politecnic La Fe
    Valencia, Spain
  • Hospital Universitario Rio Ortega
    Valladolid, Spain
  • Hospital Miguel Servet
    Zaragoza, Spain
09

References and documents

Publications

  • Barret JP, Podmelle F, Lipovy B, Rennekampff HO, Schumann H, Schwieger-Briel A, Zahn TR, Metelmann HR; BSH-12 and BSG-12 study groups. Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program. Burns. 2017 Sep;43(6):1284-1294. doi: 10.1016/j.burns.2017.03.005. Epub 2017 Apr 8. PubMed 28400148 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Sep 2013 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2013
First posted
Mar 8, 2013
Start
Mar 2013
Primary completionActual
Sep 2013
CompletionActual
Sep 2014
Results first posted
Jul 19, 2018
Last update
Jul 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01807650
Lead sponsor
Birken AG
Responsible party
Sponsor
First posted
Mar 8, 2013
Start date
Mar 2013
Primary completion
Sep 2013
Completion
Sep 2014
Results posted
Jul 19, 2018
Last update
Jul 19, 2018

Study contacts

Juan Pedro Barret Nerin, MD
principal investigator · Hospital Universitari Vall d´Hebron, Barcelona, Spain

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Episalvan

Start the discussion